The Global Pharmacogenomics Market, by Technology Type (Polymerase Chain Reaction, Sequencing, Microarray, and Other Technologies), and by Application (Drug Discovery and Therapeutic Application) was valued at US$ 8,357.3 million in 2017 and is projected to expand at a CAGR of 10.8% during the forecast period (2018-2026), as highlighted in a new report published by Coherent Market Insights. Advancements in technology, increasing developments by key players, rising prevalence of lifestyle related diseases are expected to contribute to meteoric growth of the pharmacogenomics market over the forecast period.
Increasing engagement of pharmaceutical companies in pharmacogenomics is increasing potential opportunities for various phases of drug discovery and development processes. In parallel with rapid advancements in the identification and mapping of Single Nucleotide Polymorphism (SNPs) across the human genome, technological discoveries and enhancements to high-throughput genotyping have also made significant strides. Leading biotech firms have driven genotyping throughput to scales and significantly driving down costs. Pharmacogenomics initiatives have led to new discoveries and development of several treatments that are tailored for specific characteristics such as genetic makeup or genetic profile of an individual tumor, that helps transform the treatment methods. Increasing government funding to help companies develop bioinformatics technology for precision medicine research applications. For instance, in 2017, Armonica Technologies, Inc., an Albuquerque-based company received US$1.5 million from the government's US $40 million catalyst fund. This fund is intended for seed early-stage companies in New Mexico that are involved in developing novel technologies.
In therapeutic application, oncology portfolio is of strategic importance for researchers to develop more targeted approaches for the treatment of cancer. For an instance, AstraZeneca oncology portfolio will increasingly rely on the use of genetics and genomics for patient identification and stratification, which in turn, provides a source of novel biomarkers and diagnostics. This allows them to streamline the R&D process and help to better understand the biological basis of the diseases that are aiming to be treated. Thus, integration of pharmacogenomics analysis results in increased designing of tailored drugs, which is expected to increase profits for drug manufacturers.
Browse 28 Market Data Tables and 31 Figures spread through 160 Pages and in-depth TOC on "" Pharmacogenomics Market, by Technology Type (Polymerase Chain Reaction, Sequencing, Microarray, and Other Technologies), and by Application (Drug Discovery and Therapeutic Application), and by Region - Global Forecast to 2026""
To know the latest trends and insights related to pharmacogenomics market, click the link below:
https://www.coherentmarketinsights.com/market-insight/pharmacogenomics-market-1053
North America is expected to witness highest growth in the global pharmacogenomics market, owing to increasing number of clinical trials for various application areas and rising biotechnology and life sciences sector in this region as well as the increasing focus on research and development by the top market players in these regions. North America is followed by Asia Pacific with the second highest growth rate during the forecast period. For instance, Thermo Fisher Scientific, in 2017, announced an Asia Precision Medicine research array for regional screening initiatives, which has reduced costs and complexity of analysis associated with whole genome sequencing to help the research of diseases among people living in Asia, which in turn, is expected to favor growth of the market in Asia Pacific.
The healthcare facilities and services in the Middle Eastern countries are underdeveloped, however, have high potential to grow in the near future. To accomplish the goal, the Middle Eastern countries are forming alliances with global leading companies as well as government organizations to foster the development of healthcare in these countries. For instance, in 2016, Middle East Medical Assembly at American University of Beirut (AUB) explored precision medicine sector, which is expected to revolutionize the healthcare and disease treatment in the Middle East, as MEMA brings physicians and experts together to discuss the latest challenges and novelties in precision medicine and genomics.
Vendors are continuously investing in the development of the pharmacogenomics for various applications in clinical and translational research to find a solution to the problems of under-served patients, misdiagnoses, adverse drug reactions (ADRs), and ineffective therapeutics, which is projected to provide lucrative growth over the forecast period. In May 2015, Rosetta Genomics Ltd. launched OncoGxOne, Admera Health's next-generation sequencing (NGS) panel that detects a vast number of genetic alterations implicated in cancer, to provide clear, concise, and actionable clinical recommendations from a single, comprehensive test.
Key Takeaways of the Pharmacogenomics Market:
The global pharmacogenomics market is expected to expand at a CAGR of 8% during the forecast period (2018-2026), due to foster collaborations among the pharmaceutical industry, academic researchers, regulators and government organizations across various regions
Increasing demand for sequencing, owing to its wide application in cancer pharmacogenetic and ability to sequence large number of genes up to the complete genome in a single reaction.
Sequencing is expected to show a meteoric growth over the forecast period, as growing awareness among federal agencies, such as the FDA and NIH, in advancing NGS research and development relevant to pharmacogenetics for personalized medicine raising the requirement in the public and private sectors
Among applications, drug discovery is the fastest growing segment, as this is an emerging field and there are currently a large number of pharmacogenomics tests to detect mutations in the genes responsible for various infectious and non-infectious diseases
Some of the major players involved in global pharmacogenomics market are Thermo Fisher Scientific Inc., Abbott Laboratories, F. Hoffmann-La Roche AG, Qiagen N.V., Pacific Biosciences of California, Inc., Diatech Pharmacogenetics Srl and Assurex Health Inc.
The global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market is expected to reach US$ XX Million by 2028, with a CAGR of XX% from 2023 to 2028, based on HNY Research newly published report.
The prime objective of this report is to provide the insights on the post COVID-...
Overview of the Global Pharmacogenomics Pharmacy Market:
The report discusses everything a marketer requires before investing in the global Pharmacogenomics Pharmacy Market during the forecast period 2023-2030. It p...
Overview of the Global Pharmacogenomics-guided Therapy Market:
The report discusses everything a marketer requires before investing in the global Pharmacogenomics-guided Therapy Market during the forecast period 202...
Overview of the Global Pharmacogenomics Services Market:
The report discusses everything a marketer requires before investing in the global Pharmacogenomics Services Market during the forecast period 2023-2030. It p...
Overview of the Global Pharmacogenomics Technology Market:
The report discusses everything a marketer requires before investing in the global Pharmacogenomics Technology Market during the forecast period 2023-2030. ...
The global Pharmacogenomics (PGx) market is expected to reach US$ XX Million by 2028, with a CAGR of XX% from 2023 to 2028, based on HNY Research newly published report.
The prime objective of this report is to provide the insights on the post COVID-19 impact which will help market players in th...
According to market research study published by Gen Consulting Company, the market size of the global pharmacogenomics sector is expected to rise by USD 7 billion with a CAGR of 10.5% by the end of 2028.
The report provides in-depth analysis and insights regarding the current global mar...
The global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market is expected to reach US$ XX Million by 2027, with a CAGR of XX% from 2022 to 2027, based on HNY Research newly published report.
The prime objective of this report is to provide the insights on the post COVID-...
The Molecular Diagnostics Market is predicted to reach US$ 21.1 billion by 2030 from US$ 21.1 billion in 2021, and to grow at a CAGR of ~5.10% between the forecast period 2022 to 2030.
The research report includes specific segments by Products/Type and by Application, by region (coun...
Overview of the Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market:The report discusses everything a marketer requires before investing in the global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market during the fore...